Back to News
Jan 15, 2026 12:50 PM

Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients

Johnson & Johnson (NYSE:JNJ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer.

The MajesTEC-9 study evaluates the efficacy and safety of Tecvayli versus the standard of care of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

Phase 3 Data Show Significant Survival

MajesTEC-9 is the second Phase 3 study to support Tecvayli regimens as a potential new standard of care as early as the first relapse.

The study showed a ...